Cardiovascular Drugs Market Research Report, Growth & Forecast

The Calcium Channel Blocker Market size is valued at USD 14.3 billion in 2025 and is projected to reach USD 23.4 billion by 2033, registering a compound annual growth rate (CAGR) of 6.37% over the for...

The global statin market size reached USD 15.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 20.3 Billion by 2033, exhibiting a growth rate (CAGR) of 2.74% during 2025-...

The global ischemic heart disease (IHD) drugs market size reached USD 6.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 9.3 Billion by 2033, exhibiting a growth rate (C...

The Global Pericarditis Drugs Market was valued at USD 4.1 billion in 2024 and is estimated to grow at a CAGR of 6.2% to reach USD 7.4 billion by 2034. Rising cardiovascular disease rates across the g...

This report can be delivered to the clients within 3 Business Days Eliquis (Apixaban) Market The global Eliquis (apixaban) market size was estimated at USD 20.70 billion in 2024 and is projected to...

This report can be delivered to the clients within 3 Business Days Peripheral Artery Disease Market The global peripheral artery disease market size was estimated at USD 7.3 billion in 2024 and is p...

According to Stratistics MRC, the Global Eisenmenger Complex Management Market is accounted for $1.36 billion in 2025 and is expected to reach $2.82 billion by 2032 growing at a CAGR of 11.0% during t...

According to Stratistics MRC, the Global Atrial Fibrillation Market is accounted for $17.6 billion in 2025 and is expected to reach $27.3 billion by 2032 growing at a CAGR of 6.5% during the forecast...

According to Stratistics MRC, the Global Acute Ischemic Stroke Diagnosis and Treatment Market is accounted for $6.4 billion in 2025 and is expected to reach $11.1 billion by 2032 growing at a CAGR of...

The global heparin market size was valued at USD 7.46 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 9.02 Billion by 2033, exhibiting a CAGR of 2.12% during 2025-2033....

... & Sales Analysis of Key Drugs Global Sickle Cell Anemia Drug Clinical Pipeline by Company & Phase Global Sickle Cell Anemia Drug Clinical Pipeline: 40 Drugs Marketed Sickle Cell Anemia Drugs: 4 Drugs Future Aspects of Global Sickle Cell Disease Treatment Market Sickle cell anemia is a blood disorder widely ...

Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request. This report will be delivered in 7-10 workin...

Coronary microvascular dysfunction (CMD) is a condition that affects the small blood vessels of the heart, leading to reduced blood flow and oxygen supply to the heart muscle, often without obstructiv...

Familial Hypercholesterolemia is a hereditary genetic disorder that causes high levels of low-density lipoprotein cholesterol (LDL-C) in the blood, leading to an increased risk of cardiovascular disea...

The global portal hypertension drugs market is experiencing significant growth, driven by several key factors that are reshaping the landscape of diagnosis, treatment, and patient care. The rising pre...

The global renal anemia market is experiencing steady expansion, supported by advancements in therapeutic modalities, increased diagnostic precision, and growing investment in healthcare infrastructur...

The global alport syndrome market is poised for substantial growth from 2023 to 2035, driven by a combination of factors, including a rising patient population, advancements in clinical research, and...

Heparin-induced thrombocytopenia (HIT) is a rare but serious immune-mediated adverse reaction to heparin, an anticoagulant widely used for preventing and treating blood clots. HIT typically occurs whe...

Hypofibrinogenemia is a rare blood disorder characterized by abnormally low levels of fibrinogen, also known as Factor, I, a critical plasma protein essential for normal blood clot formation. Without...

The global pulmonary hypertension market is driven by the increasing prevalence of chronic conditions such as connective tissue diseases, congenital heart disease, and chronic obstructive pulmonary di...

Eisenmenger Complex is a complex cardiovascular disorder that develops from untreated congenital heart defects, causing pulmonary hypertension and cyanosis. There is no curative therapy, and managemen...

The global Hemophilia with Inhibitor market demonstrated significant value in 2024 and is projected to expand substantially by 2035, driven by a robust compound annual growth rate during the forecast...